##common.pageHeaderLogo.altText##

Original article

Vol. 156 No. 1 (2026)

Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation

Cite this as:
Swiss Med Wkly. 2026;156:4711
Published
31.01.2026

Summary

AIMS OF THE STUDY: Marketing authorisation of the bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) for maternal vaccination was predominantly based on safety and efficacy findings from the pivotal global phase 3 Maternal Immunization Study for Safety and Efficacy (MATISSE) trial that included >7000 pregnant women and their infants. The aim of this post hoc analysis was to evaluate clinical efficacy and safety endpoints within the subgroup of participants from the MATISSE trial who received RSVpreF or placebo at 32−36 weeks of gestation, which is the indicated gestational age (GA) window for maternal RSVpreF vaccination in Switzerland.

METHODS: Healthy pregnant women ≤49 years of age with uncomplicated, singleton pregnancies were randomised 1:1 to receive a single dose of RSVpreF 120 μg or placebo. Primary efficacy endpoints were vaccine efficacy against severe medically attended RSV-associated lower respiratory tract illness and medically attended RSV-associated lower respiratory tract illness in infants occurring within 90 and 180 days after birth. This is a descriptive post hoc analysis of efficacy and safety endpoints from MATISSE among the subgroup of newborns whose mothers received RSVpreF or placebo at 32–36 weeks of gestation.

RESULTS: Of 7392 maternal participants included in the primary MATISSE analysis, 3285 (RSVpreF: 1653; placebo: 1632) received vaccination at a GA of 32–36 weeks and were included in this analysis. Efficacy was evaluated in a total of 1628 and 1604 infants who were born to mothers receiving RSVpreF or placebo, respectively. RSVpreF vaccine efficacy percentages against severe medically attended RSV-associated lower respiratory tract illness were 91.1% (95% CI: 38.8–99.8%) and 76.5% (95% CI: 41.3–92.1%) within 90 and 180 days of birth, respectively. RSVpreF vaccine efficacy percentages against medically attended RSV-associated lower respiratory tract illness were 34.7% (95% CI: –34.6–69.3%) and 57.3% (95% CI: 29.8–74.7%) within 90 and 180 days of birth, respectively. Adverse event profiles for maternal and infant participants were generally similar between RSVpreF and placebo groups in this post hoc analysis; safety results were consistent with those of the primary and final analyses.

CONCLUSIONS: Maternal vaccination with RSVpreF in pregnant women at 32−36 weeks of gestation is safe and efficacious against RSV-associated lower respiratory tract illness in infants to 6 months of age, aligning with the outcomes of the primary analysis.

ClinicalTrials.gov: NCT04424316

References

  1. 1. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al.; Respiratory Virus Global Epidemiology Network; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May;399(10340):2047–64. doi: https://doi.org/10.1016/S0140-6736(22)00478-0
  2. 2. Kampmann B, Madhi SA, Munjal I, Simões EA, Pahud BA, Llapur C, et al.; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023 Apr;388(16):1451–64. doi: https://doi.org/10.1056/NEJMoa2216480
  3. 3. ABRYSVO (RSVpreF). Full Prescribing Information. New York (NY): Pfizer Inc; 2023.
  4. 4. ABRYSVO (RSVpreF). Summary of Product Characteristics. Bruxelles, Belgium: Pfizer Europe MA EEIG; 2023.
  5. 5. Electronic Medicines Compendium. Package leaflet: Information for the user. Abrysvo® powder and solvent for solution for injection. Available at: https://www.medicines.org.uk/emc/files/pil.15309.pdf. Accessed April 8, 2025.
  6. 6. Swiss Agency for Therapeutic Products. Swissmedic Journal 08/2024. Swissmedic. Available at: https://www.swissmedic.ch/swissmedic/en/home/about-us/publications/swissmedic-journal/swissmedic-journal-2024.html. Accessed April 21, 2025.
  7. 7. Swiss Federal Office of Public Health. BAG-Bulletin 47/2024 (18 November 2024). Available at: https://www.bag.admin.ch/dam/de/sd-web/g0ZwfShEIyXp/bu-47-24.pdf
  8. 8. Jones CE, Munoz FM, Spiegel HM, Heininger U, Zuber PL, Edwards KM, et al.; Brighton Collaboration Immunization in Pregnancy Working Group. Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine. 2016 Dec;34(49):5998–6006. doi: https://doi.org/10.1016/j.vaccine.2016.07.032
  9. 9. Roberts JN, Gruber MF. Regulatory considerations in the clinical development of vaccines indicated for use during pregnancy. Vaccine. 2015 Feb;33(8):966–72. doi: https://doi.org/10.1016/j.vaccine.2014.12.068
  10. 10. Chan IS, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods. 1998;27(6):1305–22. doi: https://doi.org/10.1080/03610929808832160
  11. 11. Simões EA, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, et al.; MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial. Obstet Gynecol. 2025 Feb;145(2):157–67. doi: https://doi.org/10.1097/AOG.0000000000005816
  12. 12. Madhi SA, Kampmann B, Simões EA, Zachariah P, Pahud BA, Radley D, et al. Preterm birth frequency and associated outcomes from the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal trial of the bivalent respiratory syncytial virus prefusion F protein vaccine. Obstet Gynecol. 2025 Feb;145(2):147–56. doi: https://doi.org/10.1097/AOG.0000000000005817